PeptideLabs Logo
PeptideLabs
All profiles

Tirzepatide

Peptide · Metabolism & GLP-1

Activates GIP and GLP-1 receptors and influences glucose regulation, appetite and food intake.

Approved for specific uses
LibraryNo account · this device only

Also known as: GIP/GLP-1 · Mounjaro · Zepbound

Use at a glance

Tirzepatide

Activates GIP and GLP-1 receptors and influences glucose regulation, appetite and food intake.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Medicine instructions · named product only

Product or source: Tirzepatide · MOUNJARO / ZEPBOUND

What amount?
2.5 mg
How often?
once per week
What time of day?
same weekday
What period?
Week 1–4
How is it used?
The named medicines are ready-made injectable solutions. Their instructions and device are product-specific.
Does it need mixing?
No. The named ready-made solutions are not mixed with water. A research powder is a different product.
View preparationCheck sources
Overview of all entries

  • Tirzepatide · Week 1–4

    Medicine instructions · named product only · MOUNJARO / ZEPBOUND

    2.5 mg · once per week · same weekday

  • Tirzepatide · Week 5+

    Medicine instructions · named product only · MOUNJARO / ZEPBOUND

    5 mg · once per week · same weekday

  • Tirzepatide · At least 4 weeks per step

    Medicine instructions · named product only · MOUNJARO / ZEPBOUND

    +2.5 mg · once per week · same weekday

More factsPeptide · Metabolism & GLP-1
Classification
Peptide · Metabolism & GLP-1
Research focus
Activates GIP and GLP-1 receptors and influences glucose regulation, appetite and food intake.
Evidence
Established
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

Current US labels start at 2.5 mg once weekly for four weeks, then 5 mg; further increases of 2.5 mg occur no sooner than every four weeks. Maintenance and maximum amounts differ by product, indication and age.

Profile evidence level: established.

Timing

Once weekly on the same day of the week per product guidance; handling of missed doses and oral contraceptives is label-specific.

No individual recommendation.

Cycle/duration

No community cycle: approved long-term treatment for defined indications under medical supervision.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No. The named ready-made solutions are not mixed with water. A research powder is a different product.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

10 mg · assumed final volume: 1 ml

Community calculation example
Calculated amount2.5 mg
Concentration10,000 µg/ml
U-10025 U
Volume0.25 ml
Calculated amount5 mg
Concentration10,000 µg/ml
U-10050 U
Volume0.5 ml

40 mg · assumed final volume: 2 ml

Community calculation example
Calculated amount2.5 mg
Concentration20,000 µg/ml
U-10012.5 U
Volume0.125 ml
Calculated amount10 mg
Concentration20,000 µg/ml
U-10050 U
Volume0.5 ml
Calculated amount15 mg
Concentration20,000 µg/ml
U-10075 U
Volume0.75 ml
All preparation informationProduct details and calculation examples from the available sources.

Mounjaro/Zepbound are ready-to-use solutions and are not reconstituted. Community arithmetic from the reference source for unapproved vials: 10 mg +1 ml =10 mg/ml; 2.5 mg would be 25 U, 5 mg 50 U. At 40 mg +2 ml =20 mg/ml, 2.5 mg would be 12.5 U, 10 mg 50 U and 15 mg 75 U. No product or dose recommendation.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

GIP and GLP-1 receptor agonist

Tirzepatide is classified as “GIP and GLP-1 receptor agonist”. Activates GIP and GLP-1 receptors and influences glucose regulation, appetite and food intake. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Dual GIP/GLP-1 action

This examines whether engaging two gut hormone receptors at once produces stronger effects on weight and blood sugar than a single receptor alone. Studies compare weight loss and metabolic markers between single- and dual-acting agents.

02

Blood sugar and appetite outcomes

Researchers study how a substance changes blood sugar levels and feelings of hunger over the course of a day, similar to tracking how full someone feels after different meals. Typical measures include blood glucose readings and questionnaires about hunger and food intake.

03

Body weight and metabolism

Researchers track changes in body weight, body composition, and metabolic markers such as blood sugar or cholesterol over the course of a study. This is similar to following someone's weight and lab values over months to see broader trends rather than day-to-day fluctuations.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Stack and blend discussion

Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.

Adverse effects and safety risks

  • Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

The dual mechanism is supported by approval trials, though long-term comparisons with other agents continue.

Clinical evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Tirzepatide acts on two receptors (GIP and GLP-1), whereas semaglutide activates only the GLP-1 receptor.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

Tirzepatide is not prohibited in 2026 but is on the WADA Monitoring Program. This is observation, not clearance for every product or contaminant.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile